Celgene in talks to buy Juno Therapeutics: report

Celgene Corp. CELG, -1.11% is in talks to shop for Juno Therapeutics Inc. JUNO, -6.46% in keeping with a record on The Wall Boulevard Magazine Tuesday that cited unnamed resources. Juno is a biotech corporate growing most cancers remedies. Juno inventory soared greater than 30% in overdue buying and selling Tuesday and ended the common buying and selling day down 6.five%. Celgene stocks rose 1% and closed the common consultation down 1.1%. Celgene previous this month launched initial fourth-quarter and full-year 2017 effects and supplied a downbeat outlook for 2018.

Related posts

Leave a Comment